Intravitreal bevacizumab in a patient with neovascular glaucoma

Malik Y. Kahook, Joel S. Schuman, Robert J. Noecker

Research output: Contribution to journalArticlepeer-review


The utility of intravitreal bevacizumab injection in a patient with neovascular glaucoma following central retinal vein occlusion is explored. Bevacizumab (1 mg in 0.04 mL) was used after failed intraocular pressure (IOP) control with transscleral cyclophotocoagulation and panretinal photocoagulation. IOP improved within 2 days and the patient experienced marked improvement in comfort. Bevacizumab may be an effective medication for the treatment of neovascular glaucoma.

Original languageEnglish (US)
Pages (from-to)144-146
Number of pages3
JournalOphthalmic Surgery Lasers and Imaging
Issue number2
StatePublished - 2006

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology


Dive into the research topics of 'Intravitreal bevacizumab in a patient with neovascular glaucoma'. Together they form a unique fingerprint.

Cite this